THEORETICAL ASPECTS OF THE USE OF BOTULINUM TOXIN AND CGRP RECEPTOR ANTAGONIST IN CHRONIC MIGRAINE AND CERVICOGENIC HEADACHE THERAPY

Abstract


The mechanisms of generation of extra-intracranial interaction of the excitation processes in the Central nervous system on models of migraine in animals were studied and described in this article. There was described the possible mechanism of relationship between migraine and cervicogenic headache. Recently there was developed innovative drug on the base of botulinum toxin A, and it was described the mechanism of its assembly and therapeutic effect. Also we have provided an overview of modern anti-migraine drugs.

About the authors

Olga S Khayrutdinova

Kazan state medical university

Email: nikonova.os@yandex.ru
420012, Kazan, Butlerov street, 49
department of neurology and rehabilitation

Rashid A Giniatullin

The University of Eastern Finland

Email: Rashid.Giniatullin@uef.fi
Kuopio, 70211, P.O.Box 1627/ Neulaniementie 2
the Department of Neurobiology

Bazbek A Davletov

The University of Sheffield

England, University of Sheffield, Sheffield S10 2TN

Rashid A Altunbaev

Kazan state medical university

Email: alturash@mail.ru
420012, Kazan, Butlerov street, 49
department of neurology and rehabilitation

References

  1. Алтунбаев Р.А., Никонова О.С. Оценка эффективности применения ботулинотерапии при лечении хронических мигренозных болей. Сборник тезисов 87-й Всероссийской научно-практической конференции молодых ученых. Казань, 2013. С. 221-222.
  2. Amin F. M., Olesen J., Ashina M. Intracranial and extracranial arteries in migraine // The Lancet Neurology. 2013. Vol. 12. P. 848-849.
  3. Aurora S. K., Winner P., Freeman M.C. Onabotu-linumtoxin A for Treatment of Chronic Migraine // Pooled Analyses of the 56-Week PREEMPT Clinical Program. Headache. 2011. Vol. 51 (9). P. 1358-1373.
  4. Bradnam L., Barry C. The Role of the Trigeminal Sensory Nuclear Complex in the Pathophysiology of Craniocervical Dystonia // J. Neurosci. 2013. Vol. 33 (47). P. 18358-8367.
  5. Cernuda-Morollón E., Martínez-Camblor P. CGRP and VIP levels as predictors of efficacy of onabotulinumtoxin type A in chronic migraine // Headache: The Journal of Head and Face Pain. Vol. 54 (6). P. 987-995.
  6. Davletov B., Bajohrs M., Binz T. Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins // Trends Neurosci. 2005. Vol. 28(8). P. 446-452.
  7. De Ru JA. Botulinum toxin-a is an effective and safe treatment for chronic migraine // Headache. 2013. Vol. 53 (7). Vol. 1165-1167.
  8. Edvinsson Lars, Linde Mattias. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate // The Lancet. 2010. Vol. 376. P. 645-655.
  9. Elvidge S. Anti-CGRP antibodies for migraine turn industry heads // Nature biotechnology. 2014. Vol. 32(8). P.707.
  10. Ferrari E., Chunjing Gu., Niranjan D. et al. Synthetic Self-Assembling Clostridial Chimera for Modulation of Sensory Functions // Bioconjugate Chemistry. 2013. Vol. 24 (10). P. 1750-1759.
  11. Ferrari E., Soloviev M., Niranjan D. et al. Assembly of Protein Building Blocks Using a Short Synthetic Peptide // Bioconjugate Chemistry. 2012. Vol. 23(3). P. 479-84.
  12. Ferrari E., Elizabeth S. M., Restani L. et al. Re-Assembled Botulinum Neurotoxin Inhibits CNS Functions without Systemic Toxicity // Toxins. 2011. Vol. 3. P. 345-355.
  13. Finkel A. G. Botulinum Toxin and the Treatment of Headache // Headache. 2011. Vol. 51(10). P. 1565-1572.
  14. Freitag F.G., Diamond S., Diamond M., Urban G. Botulinum Toxin Type A in the Treatment of Chronic Migraine without Medication Overuse // Headache. 2008. Vol. 48(2). P. 201-209.
  15. Freitag F.G. Botulinum toxin type A in chronic migraine // Neurother. 2007. Vol. 7(5). P. 463-770.
  16. Gady J., Ferneini E.M. Botulinum toxin A and headache treatment // Conn. Med. 2013. Vol. 77(3). P.165-166.
  17. Ho T.W., Connor K.M., Zhang Y. et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migrane prevention // Neurology. 2014. Vol. 83 (11). P. 958-966.
  18. Jackson J. L., Kuriyama A., Hayashino Y. Botulinum Toxin A for Prophylactic Treatment of Migraine and Tension Headaches in Adults // J.A.M.A. 2012. Vol. 307(16). P.1736-1745.
  19. Lin K.H., Chen S.P., Fuh J.L. et al. Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: A retrospective study // Chin. Med. Assoc. 2014. Vol. 77(1). P. 10-15.
  20. Olesen J. Highlights in headache research in 2013 // The Lancet Neurology. 2014. Vol. 13. P. 5-7.
  21. Rapoport A.M. New treatments for acute migraine // Neurol. Sci. 2010. Vol. 31 (1). P. 129-132.
  22. Ray B.S., Wolff H.G. Experimental studies on headache pain. Pain-sensitive structures of the head and their significance in headache // Arch Surg. 1940. Vol. 41. P. 813-856.
  23. Schuelera M., Messlinger K., Dux M. et al. Extracranial projections of meningeal afferents and their impact on meningeal nociception and headache // PAIN. 2013. Vol. 154. P. 1622-1631.
  24. Law S., Derry S., Moore R.A. Sumatriptan plus naproxen for acute migraine attacks in adults // Cochrane Database of Systematic Reviews. 2013. № 10. doi: 10.1002/14651858.CD008541.pub2.
  25. Yu-Feng Shao, Yi Zhang. Botulinum Toxin Type A Therapy in Migraine: Preclinical and Clinical Trials. Iranian Red Crescent Medical Journal. 2013. Vol. 15. (10). e7704. doi: 10.5812/ircmj.7704

Statistics

Views

Abstract - 576

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2014 Khayrutdinova O.S., Giniatullin R.A., Davletov B.A., Altunbaev R.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies